Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmyriaASX:EMD 3-Year EPS without NRI Growth Rate is 22.20% as of Jun. 2026, which is 13% above its 10-year median of 19.70. The stock has 4 warning signs investors should review. Among 502 Healthcare Providers & Services companies, Emyria ranks better than 63.15% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 22.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Emyria was 36.20% per year. The lowest was 16.10% per year. And the median was 19.70% per year.
Emyria (ASX:EMD) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Emyria 3-Year EPS without NRI Growth Rate Related Terms
ASX:EMD vs VEEV, BTSG, TEM: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Emyria's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emyria 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Emyria's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Emyria's 3-Year EPS without NRI Growth Rate falls into.
Emyria 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 22.20% mean?
Emyria (ASX:EMD) has a 3-Year EPS without NRI Growth Rate of 22.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Emyria and its competitors. This is 13% above median its historical median of 19.70. Over the past decade, Emyria's 3-Year EPS without NRI Growth Rate has ranged from 16.10 to 36.20. According to the industry distribution chart, Emyria ranks #185 out of 502 companies in the Healthcare Providers & Services industry, placing it in the top 36.9%.
Is Emyria's 3-Year EPS without NRI Growth Rate too high?
Emyria's current 3-Year EPS without NRI Growth Rate of 22.20% is 13% above median its 10-year median of 19.70. Over the past 10 years, this metric has ranged from a low of 16.10 to a high of 36.20. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 10.70. Emyria's value of 22.20% is 107.5% above this industry median. Based on the distribution chart, Emyria ranks #185 out of 502 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Emyria's 3-Year EPS without NRI Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Emyria ranks #185 out of 502 companies for 3-Year EPS without NRI Growth Rate. This puts Emyria in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.70. Emyria's value of 22.20% is 107.5% above this benchmark. Historically, Emyria's own 3-Year EPS without NRI Growth Rate has ranged from 16.10 to 36.20 over the past decade. While the company's 10-year median is 19.70 vs. the industry median of 10.70, Emyria has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 10.70, based on 502 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emyria's current 3-Year EPS without NRI Growth Rate of 22.20% is 107.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Emyria and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emyria's current 3-Year EPS without NRI Growth Rate is 22.20%, which is 13% above median its own 10-year median of 19.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Fairly Valued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.05 — trading 4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 22.20%, which is 13% above median its 10-year median of 19.70 and 107.5% above the Healthcare Providers & Services industry median of 10.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Emyria (ASX:EMD), the current 3-Year EPS without NRI Growth Rate is 22.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMD has been successfully added to your 
